Rockefeller Capital Management
KRYS icon

Rockefeller Capital Management’s Krystal Biotech KRYS Stock Holding History

Rockefeller Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$59.7K Buy
231
+175
+313% +$46.6K ﹤0.01% 3174
2025
Q4 		$13.8K Sell
56
-49
-47% -$10.3K ﹤0.01% 3670
2025
Q3 		$18.5K Buy
+105
New +$15.7K ﹤0.01% 3384
2022
Q3 		– Sell
-42
Closed -$2K – 4154
2022
Q2 		$2K Buy
+42
New +$2.61K ﹤0.01% 3800

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rockefeller Capital Management's KRYS Position: Q1 2026 in Review

Rockefeller Capital Management increased its Krystal Biotech (KRYS) stake by 313% in Q1 2026, buying an estimated $46.6K and bringing the position to 231 shares worth $59.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3174.

Rockefeller Capital Management first reported a position in KRYS in Q2 2022 and has held it in 4 quarters since. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Rockefeller Capital Management held 231 shares of Krystal Biotech worth $59.7K as of Q1 2026.
  • Rockefeller Capital Management bought 175 Krystal Biotech shares in Q1 2026, an estimated $46.6K.
  • Krystal Biotech made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #3174 holding.
  • Rockefeller Capital Management first reported a position in Krystal Biotech in Q2 2022 and has held it in 4 quarters since.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.